30.07.19: Half-Year Report 2019
Half-Year Report 2019Link to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 13, 2018 Category: Pharmaceuticals Source Type: news
30.10.19: Q3 2019 Quarterly Statement
Q3 2019 Quarterly StatementLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 13, 2018 Category: Pharmaceuticals Source Type: news
13.11.18: Third quarter of 2018
Bayer: Good performance in a challenging environment, Group outlook confirmedGroup sales increase by 1.9 percent (Fx & portfolio adj.) to 9.905 billion euros / EBITDA before special items level year on year at 2.202 billion euros / Business performance at Pharmaceuticals remains strong / Consumer Health with increase in sales (Fx & portfolio adj.), while currency effects weigh on earnings / Crop Science posts substantial rise in sales and earnings due to acquisition - successful start to integration process / Sales and earnings of Animal Health decline following a strong second quarter / One-time gain (before taxes) of rou...
Source: Bayer IR Newsfeed: Events - November 13, 2018 Category: Pharmaceuticals Source Type: news
13.11.18: Q3 2018 News Conference Call
Q3 2018 News Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2018 Category: Pharmaceuticals Source Type: news
13.11.18: Q3 2018 Investor Conference Call
Q3 2018 Investor Conference CallLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 30, 2018 Category: Pharmaceuticals Source Type: news
24.10.18: Not intended for U.S. and UK Media
Phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer meets primary endpointThe safety and tolerability observed in the trial were consistent with previously published data on darolutamidemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 24, 2018 Category: Pharmaceuticals Source Type: news
21.10.18: Not intended for U.S. and UK Media - ESMO 2018 Congress (European Society for Medical Oncology)
Expanded larotrectinib data confirm findings on efficacy and safety in adult and pediatric patients with TRK fusion cancer across various tumor typesData presented across 122 adult and pediatric patients (55 patients from primary dataset plus supplementary dataset with 67 additional patients) with TRK fusion cancer across various tumor types / Integrated dataset on larotrectinib demonstrated high overall response rate of 81 percent (63 percent partial responses and 17 percent complete responses), per investigator assessment / For the initial 55 patients, ongoing responses at 12 months improved to 75 percent with longer fol...
Source: Bayer IR Newsfeed: Events - October 21, 2018 Category: Pharmaceuticals Source Type: news
12.10.18: Not intended for U.S. and UK Media
U.S. FDA approves Bayer's Xarelto® for patients with coronary or peripheral artery diseaseXarelto, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease / Xarelto, in combination with aspirin, is the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient group / Approval in the U.S. follows regulatory clearance in both Europe and Canadamehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - October 12, 2018 Category: Pharmaceuticals Source Type: news
21.09.18: Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027The safety and efficacy profile of BAY94-9027 has been demonstrated in more than five years of clinical studies / Prophylaxis with BAY94-9027 enables sustained factor VIII concentrations in the blood over timemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 21, 2018 Category: Pharmaceuticals Source Type: news
21.09.18: Not intended for U.S. and UK Media
Bayer's Jivi® approved in Japan for hemophilia Amehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 20, 2018 Category: Pharmaceuticals Source Type: news
05.12.18: Capital Markets Day, London
Capital Markets Day, LondonLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 18, 2018 Category: Pharmaceuticals Source Type: news
13.09.18: Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals Division
Stefan Oelrich to join Bayer Board of Management and head Pharmaceuticals DivisionDieter Weinand leaving the company as of November 1, 2018 / Contract extensions for Board of Management members Liam Condon and Dr. Hartmut Klusikmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 13, 2018 Category: Pharmaceuticals Source Type: news
12.09.18: Bank of America Merrill Lynch Global Healthcare Conference, London
Bank of America Merrill Lynch Global Healthcare Conference, LondonLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 11, 2018 Category: Pharmaceuticals Source Type: news
07.09.18: Roadshow Zurich
Roadshow ZurichLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 6, 2018 Category: Pharmaceuticals Source Type: news
06.09.18: Roadshow Frankfurt
Roadshow FrankfurtLink to website (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - September 5, 2018 Category: Pharmaceuticals Source Type: news
